In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases

阿兹屈南 铜绿假单胞菌 微生物学 最小抑制浓度 生物 细菌 抗生素 头孢他啶 遗传学
作者
Christophe Le Terrier,Patrice Nordmann,Laurent Poirel
出处
期刊:Journal of Antimicrobial Chemotherapy [Oxford University Press]
卷期号:78 (1): 101-107 被引量:13
标识
DOI:10.1093/jac/dkac360
摘要

To evaluate the in vitro activity of aztreonam in combination with novel β-lactamase inhibitors, namely avibactam, nacubactam, taniborbactam and zidebactam, against MDR MBL-producing Enterobacterales and Pseudomonas aeruginosa clinical isolates.MIC values of aztreonam, aztreonam/β-lactam inhibitor but also cefiderocol as comparator were determined for 64 and 39 clinical Enterobacterales or P. aeruginosa isolates, respectively, producing representative MBLs, i.e. derivatives of NDM (n = 64), VIM (n = 32), IMP (n = 8) and SPM (n = 2). MICs were also determined for Escherichia coli TOP10 and P. aeruginosa PAO1 harbouring recombinant plasmids producing the different β-lactamases under isogenic backgrounds (n = 22 and n = 11, respectively). Fifty percent inhibitory concentrations were additionally determined for the abovementioned β-lactamase inhibitors using β-lactamase crude extracts.The susceptibility rate for aztreonam was 17.1% among MBL-producing Enterobacterales, while it was very high with aztreonam/zidebactam (98.4%), and to a lower extent with aztreonam/nacubactam (84.4%) and aztreonam/taniborbactam (75%), compared with aztreonam/avibactam (70.3%) and cefiderocol (39.1%). Among MBL-producing P. aeruginosa isolates, the susceptibility rates were 53.8% with aztreonam, 66.7% with aztreonam/nacubactam and aztreonam/taniborbactam combinations, and 69.2% with aztreonam/avibactam, aztreonam/zidebactam and cefiderocol.Altogether, these results showed that combinations including aztreonam and novel β-lactamase inhibitors, such as zidebactam, nacubactam or taniborbactam, have a very significant in vitro activity against MDR MBL-producing Enterobacterales clinical isolates, the aztreonam/zidebactam combination being the best option. On the other hand, aztreonam/zidebactam is equivalent to aztreonam/avibactam and cefiderocol among MBL-producing P. aeruginosa isolates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
你里其发布了新的文献求助50
1秒前
1秒前
卫卫完成签到 ,获得积分10
1秒前
haitianluna完成签到,获得积分10
2秒前
搜集达人应助ruby采纳,获得10
2秒前
小豆包发布了新的文献求助10
2秒前
要读睡着了完成签到,获得积分10
2秒前
柚子完成签到,获得积分10
2秒前
呼呼呼发布了新的文献求助10
3秒前
桃子完成签到,获得积分10
3秒前
小刀发布了新的文献求助10
3秒前
明亮的小兔子完成签到 ,获得积分10
3秒前
4秒前
科研通AI6.4应助槑槑采纳,获得10
4秒前
科目三应助snow采纳,获得10
4秒前
科研通AI6.2应助wangyucode采纳,获得10
4秒前
科研通AI6.2应助wangyucode采纳,获得10
4秒前
斯文败类应助wangyucode采纳,获得10
5秒前
5秒前
科研通AI6.2应助wangyucode采纳,获得10
5秒前
豆芽完成签到,获得积分10
5秒前
weiyi发布了新的文献求助10
5秒前
an发布了新的文献求助10
5秒前
5秒前
haitianluna发布了新的文献求助10
6秒前
Iris发布了新的文献求助10
6秒前
8秒前
倪大业666完成签到 ,获得积分10
8秒前
大可发布了新的文献求助10
9秒前
9秒前
9秒前
周一发布了新的文献求助10
10秒前
豆芽发布了新的文献求助10
11秒前
11秒前
Owen应助要读睡着了采纳,获得10
11秒前
Wen完成签到,获得积分10
11秒前
田様应助xiaqiang采纳,获得10
11秒前
一番完成签到,获得积分10
12秒前
杨新苗发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
2016 Venous Blood Study (VBS) (Final V3.0) 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
The Effective Clinical Neurologist 3ed 500
The Great Hymn to Šamaš 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7701971
求助须知:如何正确求助?哪些是违规求助? 9260779
关于积分的说明 20028160
捐赠科研通 7277679
什么是DOI,文献DOI怎么找? 3294103
关于科研通互助平台的介绍 2449576
邀请新用户注册赠送积分活动 2300715